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The high prevalence of Mycobacterium tuberculosis makes it imperative that immune responses to evaluate
could be predictive of infection. We investigated liveMycobacterium- and recombinant antigen-induced cytokine
and chemokine responses in patients with active tuberculosis (TB) compared with those of healthy controls
from an area where TB is endemic (ECs). M. tuberculosis-, M. bovis BCG-, ESAT6-, and culture filtrate protein
10 (CFP10)-induced responses were determined in peripheral blood mononuclear cells from patients with
pulmonary TB (n  38) and ECs (n  39). The levels of the cytokines gamma interferon (IFN-) and
interleukin-10 (IL-10) and the chemokines CCL2, CCL3, and CXCL9 were measured. The levels of M.
tuberculosis- and BCG-induced IFN- secretion were significantly reduced (P  0.002 and P < 0.01, respec-
tively), while the amount of IL-10 induced by both virulent (P < 0.01) and avirulent (P  0.002) mycobacteria
was increased in patients with TB. The ESAT6-induced IFN- responses were increased in the patients with
TB (P  0.013) compared with those in the EC group. When tuberculin skin test (TST)-negative (TST;
induration, <10 mm) and TST-positive (TST) donors were studied separately, both TST and TST
individuals showed increased IFN- responses to M. tuberculosis compared with the responses of the patients
with TB (P  0.037 and P  0.006, respectively). However, only TST ECs showed reduced IFN- responses
to ESAT6 (P  0.008) compared with the responses of the patients with TB. The levels of M. tuberculosis-
induced CCL2 (P  0.006) and CXCL9 (P  0.017) were greater in the patients with TB. The levels of CCL3
secretion in response to Mycobacterium and antigen stimulation were comparable between the two groups.
While the levels of ESAT6-induced chemokines did not differ between the patients with TB and the ECs, the
levels of CFP10-induced CCL2 (P  0.01) and CXCL9 (P  0.001) were increased in the patients. These data
indicate differential host IFN-, CXCL9, and CCL2 responses to live mycobacteria and mycobacterial antigens
and have implications for the identification of potential biomarkers of infection which could be used for the
diagnosis of TB.
Tuberculosis (TB) remains an important cause of mortality
and morbidity worldwide, causing 2 million deaths annually.
Vaccination with Mycobacterium bovis BCG provides protec-
tion mostly during childhood and primarily against the ex-
trapulmonary forms of the disease (28, 45, 49). It is important
to identify immune markers that may be reflective of natural
infection in the host and that may therefore be useful in pre-
dicting the outcome of the disease.
Host immune responses determine the outcome of M. tuber-
culosis infection. The balance between the key T-cell cytokines
gamma interferon (IFN-) and interleukin-10 (IL-10), which
are produced by macrophages and subsets of T cells, is key to
the maintenance of effector responses against the mycobacte-
rium (13, 34). This is further reflected by the relationship
between IFN- and IL-10, which differs according to the se-
verity of the disease, especially in patients with extrapulmonary
M. tuberculosis infections (24).
The formation and maintenance of granulomas are essential
for the control of mycobacterial infections. Tumor necrosis
factor alpha (TNF-) is critical to an effective response against
M. tuberculosis and for efficient granuloma formation (38).
TNF/ mice show increased pathology and a more rapid
progression of disease during infection with M. tuberculosis (6).
IFN-- and macrophage-induced TNF- activates and reg-
ulates the C-C chemokines CCL2, CCL3, CCL4, and CCL5
and the C-X-C chemokines CXCL8, CXCL9, CXCL10, and
CXCL11 (2) (42). These chemokines have been shown to play
an important role in the recruitment and activation of leuko-
cytes at the site of granuloma formation.
CCL2 is the most potent activator of monocytes and is es-
sential for recruitment and migration to the lung. Studies with
CCL2/ mice have investigated the pathology of M. tubercu-
losis infection (26) and have shown that CCCR2/ mice ex-
hibit faulty granuloma formation and increased susceptibility
to disease caused by M. tuberculosis (44). IFN--activated che-
mokines, such as CXCL9 and CXCL10, are induced by M.
tuberculosis antigens (1, 40).
The circulating levels of cytokines such as IFN-, IL-10,
transforming growth factor-, and chemokine CXCL9 are
found to be raised in patients with TB (17, 33). Patients with
pulmonary TB also display increases in the level of monocyte-
activating chemokine CCL2 (20). An increase in the CCL2
* Corresponding author. Mailing address: Department of Pathology
and Microbiology, P.O. Box 3500, Aga Khan University, Stadium
Road, Karachi 74800, Pakistan. Phone: 92 21 486 4511. Fax: 92 21 493
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level is associated with monocyte migration to the lung and the
reduced progression of disease (26, 43). Recent studies have
identified molecular mechanisms which are deficient in pa-
tients with pulmonary TB. These include reduced IFN- re-
sponses at the disease site (21) and a reduced monocyte mat-
uration ability concomitant with a reduction in the levels of
markers of antigen presentation, such as major histocompati-
bility complex class II expression (36). In addition, it has been
shown that granulomas differ in cavitary and noncavitary TB
(48). This further emphasizes the need to understand the pat-
tern of recognition of mycobacterial antigens in different forms
of TB and in transitions from latent to active infection.
Six-kilodalton early secreted antigenic target 6 (ESAT6) and
culture filtrate protein 10 (CFP10) are both encoded by region
of difference 1 (RD1), which is present in M. tuberculosis and
M. bovis but which is absent from M. bovis BCG and most
environmental mycobacteria (8, 16). ESAT6 is an immuno-
dominant T-cell-stimulatory antigen and is recognized by spe-
cific IFN--secreting T cells that are present in greater num-
bers in patients with active disease than in those who are
uninfected (37, 47). The importance of these recombinant an-
tigens is in their immune recognition by T cells specific to
infected individuals. They are a primary component of new
diagnostic assays and are meant to detect latent infections in
individuals because of their lack of cross-reactivity with M.
bovis BCG, which is used for vaccination (27). Commercial
tests that use IFN--release assays are increasingly available as
diagnostic and predictive tests for newer-generation vaccines.
ESAT6- and CFP10-induced IFN- responses have been
shown to be useful in discriminating infected individuals from
healthy controls (1, 9, 46). Demissie et al. have shown that
immune responses to ESAT6 are more likely to be associated
with active infection and that a dormancy-related antigen
(HspX or -crystallin) might be a better marker of latency in
patients with TB, while cross-reactive antigens, such as the
antigen 85A complex, do not distinguish between active and
latent TB (11).
Antigen recognition and binding to cell surface receptors
result in cytokine activation and intracellular signaling cas-
cades within the host cell (14, 39). Virulent M. tuberculosis
organisms are efficient at evading macrophage host defenses,
such as phagolysosome fusion; downregulation of the activa-
tion of proinflammatory cytokines, such as TNF-; inhibition
of antigen presentation; and also host apoptotic responses (19,
25). In contrast, avirulent mycobacteria, such as the M. bovis
BCG strain, are processed along the endosomal pathway, ac-
tivating stronger responses of proinflammatory cytokines, such
as TNF-, IL-2, and IL-6, than the responses activated by
virulent mycobacteria (7). In addition, the uptake and process-
ing of live and dead mycobacteria differ in host cells (18).
Therefore, although both mycobacteria and mycobacterial an-
tigens can stimulate host immunity, it is likely that their im-
munogenicities may differ due to processing and presentation
of antigens.
There is as yet a limited understanding of how host cell
responses differ when the host is challenged with live myco-
bacteria as opposed to mycobacterial antigens. We investigated
the differential cytokine responses to live mycobacteria (viru-
lent M. tuberculosis and avirulent M. bovis BCG strains) and
compared them with those to the M. tuberculosis antigens
ESAT6 and CFP10. BCG vaccination is widespread in Paki-
stan and since 1981 has routinely been administered at birth
through the Expanded Program for Immunization (51). There-
fore, the levels of cytokine and chemokine secretion by periph-
eral blood mononuclear cells (PBMCs) in response to different
stimuli were analyzed in patients with pulmonary TB and were
compared with those in healthy vaccinated controls from areas
where TB is endemic (ECs). Our results highlight the variabil-
ity of host responses to mycobacteria and mycobacterial anti-
gens.
MATERIALS AND METHODS
Subject selection. This was a cross-sectional study comparing the PBMC re-
sponses of patients with TB with those of BCG-vaccinated healthy donors.
Thirty-eight patients with pulmonary TB were recruited from the outpatient
clinics of Aga Khan University Hospital and Medical College (AKUH) and
Masoomeen Hospital, Karachi, Pakistan. All the subjects were unrelated and
were from different parts of urban Karachi. All study subjects were examined,
evaluated, and recruited by infectious diseases consultants. The patients were
either newly diagnosed with the disease or had taken less than 7 days of antitu-
berculous therapy. All samples were taken after the participants has provided
written informed consent. The study received the approval of the Ethical Review
Committee of AKUH. The patients had no significant comorbid conditions,
including diabetes mellitus, chronic renal failure, or chronic liver disease, and
also were not receiving any corticosteroid therapy. Although Pakistan is a setting
with a low prevalence of human immunodeficiency virus (HIV) infection, all
patients were screened for HIV and tested negative.
The diagnosis of TB was based on clinical examination, chest X ray, Zeihl-
Neelsen staining of sputum for acid-fast bacilli (AFB), culture for AFB, and/or
the clinical response to treatment (as assessed by the resolution of fever and
cough and weight gain). All patients with pulmonary TB had a positive chest X
ray, with the findings being consistent with active TB, as evaluated by one of the
consulting physicians. All patients showed a favorable clinical response to anti-
tuberculous therapy. The patients were diagnosed as having minimal, moderate,
or advanced pulmonary TB by using modified classifications of the National
Tuberculosis Association of the United States on the basis of the extent of lung
tissue involvement (10, 22). Among the patients with pulmonary TB, 10 had
minimal disease, while 28 had moderate disease. The patient group comprised 24
females and 14 males, and the mean age was 28.2  12.3 years.
BCG-vaccinated asymptomatic healthy staff at AKUH (mean age, 28.1  6.6
years) with no known exposure to TB were used as ECs. The healthy control
group comprised 22 females and 17 males. No member of the control group had
a household member with TB, nor did they have any relationship to any of the
patients recruited in the study. All volunteers had a normal chest X ray. The
tuberculin skin test (TST) was performed by the intradermal administration of 5
tuberculin units on the volar surface of the right arm, and the result was read by
a single reader 48 h later. An induration of 10 mm was used as a cutoff for a
positive response. Both TST-negative (TST; n  21) and TST-positive (TST;
n  18) ECs were included in the study.
Mycobacterium culture. M. tuberculosis H37Rv was acquired from ATCC. M.
bovis BCG (Montreal vaccine strain) was used as described previously (19). All
strains were grown to logarithmic phase in 7H9 Middlebrook medium supple-
mented with 0.02% glycerol, 10% albumin-dextrose-catalase Middlebrook en-
richment, and 0.5% Tween 80 (all from Difco Laboratories, Detroit, MI). Ali-
quots of mycobacteria at 2  106 CFU/ml were frozen in growth medium
containing 15% glycerol and were stored at 70°C. For the infection assay,
aliquots of mycobacteria were freshly thawed, washed three times in phosphate-
buffered saline, and diluted as required for the infection. To avoid clumping of
the mycobacteria, the cell suspension was briefly sonicated and was then allowed
to stand for 5 min to allow the large clumps to settle, leaving behind a suspension
of single cells (19). The mycobacterial inoculum was also plated out for each
assay to determine bacterial viability, which was greater than 80% in each case.
Reagents. Recombinant antigens ESAT6 and CFP10 were obtained through
the TB Vaccine Testing and Research Materials Contract (contract NO1-A1-
40091), NIH, NIAID, awarded to Colorado State University.
Isolation and stimulation of PBMCs. PBMCs were obtained by gradient sep-
aration of whole blood with Histopaque (Gibco-BRL). The cells were counted
with a hemacytometer and plated at 2  105 per well in a 24-well tissue culture
plate. Bacterial inocula were made in a volume of 250 	l RPMI medium, which
was added to each well containing 2 105 PBMCs. Subsequently, the cell culture
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volume of each well was made up to 1 ml containing 10% autologous serum in
RPMI medium.
The time course and the dose-response of the M. tuberculosis and BCG
infection of PBMCs was performed with PBMCs from healthy donors (n  10).
Two concentrations of the mycobacteria, 2 105 CFU/ml (infection ratio, 1) and
106 CFU/ml (infection ratio, 5), were employed. The levels of IFN- secretion in
response to M. tuberculosis and M. bovis BCG infection of PBMCs from healthy
control donors were determined at 18 and 48 h postinfection.
The BCG-induced IFN- responses did not show any significant difference
between infection with 2  105 CFU/ml (1,627  2,169 pg/ml) and 106 CFU/ml
(1,831  2,088 pg/ml) at 18 h. At 48 h, the trend was for the level of IFN-
secretion to be greater with infection with 2 105 CFU/ml (3,794 2,621 pg/ml)
than with infection with 106 CFU/ml (2,703  2,581 pg/ml), but there was no
significant difference between the doses. Similar trends were observed with the
dose-response curve for M. tuberculosis-stimulated PBMCs, except that the trend
in the level of IFN- secretion was lower in response to the virulent bacilli at 2
105 CFU/ml (1,347  3,107 pg/ml) than in response to the virulent bacilli at 106
CFU/ml (1,604  1,796 pg/ml), confirming previous results (19).
For the remaining experiments, PBMCs were infected with M. tuberculosis or
M. bovis BCG at 2  105 CFU/ml to obtain an infection ratio of 1 per cell.
Although an increase in the level of Mycobacterium-induced cytokine secretion
was observed at 48 h poststimulation compared with that observed at 18 h
poststimulation, we found that the levels at the earlier time point were more
suitable for use for the study of cytokine secretion, as there was a greater change
in the levels during the earlier period.
A dose-response curve for the ESAT6 and CFP10 antigen stimulation exper-
iments was also determined with concentrations of 2.5, 5, and 10 	g/ml. On the
basis of the trends in IFN- secretion observed in response to antigen stimulation
of PBMCs, we determined that a concentration of 5 	g/ml measured at 18 h
poststimulation was optimal for these experiments (data not shown).
PBMCs were also stimulated with ESAT6 (5 	g/ml) and CFP10 (5 	g/ml). All
supernatants were collected at 18 to 20 h poststimulation for the measurement of
cytokine and chemokine levels. Samples were centrifuged to collect any cellular
debris, aliquoted, and stored at 70°C until they were tested.
ELISAs for IFN-, IL-10, CCL2, CCL3, and CXCL9. IFN- and IL-10 secre-
tion was detected in cellular supernatants by using standards and enzyme-linked
immunosorbent assay (ELISA) reagents obtained from Endogen (Rockford, IL).
Cytokine levels were measured by a sandwich ELISA technique, according to the
manufacturer’s instructions and as reported previously (20). Recombinant hu-
man cytokine was used to obtain a dose-response curve with a range of detection
of from 3.9 to 1,000 pg/ml. All experimental samples were tested in duplicate.
CCL2, CCL3, and CXCL9 standards and monoclonal antibody pairs for cap-
ture and detection were obtained from R&D Systems (Abingdon, United King-
dom). All measurements were carried out according to the manufacturer’s rec-
ommendations and as described previously (20). Recombinant human cytokine
was used to obtain a dose-response curve with ranges of detection of from 6.25
to 500 pg/ml for CXCL9 and 6.25 to 1,000 pg/ml for CCL2.
Statistical analysis. Data are represented by box plots that illustrate the 25th
and 75th quartiles and the medians, shown as horizontal bars. Nonparametric
statistical analysis was performed by using the Kruskal-Wallis and Mann-Whit-
ney U tests, as required. Spearman’s rank correlation was also performed. All
analyses were performed with Statistical Package for Social Sciences software
(SPSS, Inc.).
RESULTS
Increased M. tuberculosis- and BCG-induced IFN- and
IL-10 levels in patients with TB. The M. tuberculosis- and M.
bovis BCG-induced IFN- responses in the patients with TB
were compared with those in healthy ECs. The levels of IFN-
and IL-10 secretion in the absence of a stimulant were negli-
gible in both the test and the control groups. The M. tubercu-
losis-induced IFN- responses were significantly reduced (P 
0.002) in the patients with TB than in the controls (Fig. 1A).
Similarly, BCG induced IFN- responses were also reduced in
the patients with TB (P 
 0.01) compared with the responses
in the controls (Fig. 1B).
We next compared the levels of IL-10 secretion in patients
and controls. In contrast to the findings for IFN-, M. tuber-
culosis-induced IL-10 levels were significantly raised in patients
compared with the levels in the controls (P 
 0.01) (Fig. 1C).
Similarly, BCG-induced IL-10 levels were also greater in the
patients with TB than in the controls (P  0.002) (Fig. 1D).
The magnitude of IL-10 induced by M. tuberculosis in the
patient group was severalfold greater than that induced by
BCG stimulation of PBMCs (P  0.047).
Mycobacterial antigens ESAT6 and CFP10 induced IFN-
and IL-10 secretion in patients with TB. To investigate
whether the M. tuberculosis-induced chemokine responses
were reflective of those induced by recombinant antigens from
the bacilli, we stimulated PBMCs with both ESAT6 and
CFP10. The ESAT6-induced IFN- responses were signifi-
cantly increased (P  0.013) in the patients with TB (median,
41 pg/ml) compared with those in the controls (median, 2
pg/ml) (data not shown), corresponding with previous findings
(9). The magnitude of IFN- secretion in response to ESAT6
in the healthy control group was also severalfold lower than
that in response to M. tuberculosis (P  0.043).
The level of ESAT6-induced IL-10 secretion was greater in
the patients with TB than in the ECs (medians, 3 and 0 pg/ml,
respectively; P  0.033). Although the IFN- responses in-
duced by CFP10 stimulation of PBMCs were stronger than
those elicited by ESAT6 stimulation of PBMCs, the responses
were comparable between the patients with TB (median, 225
pg/ml) and ECs (median, 135 pg/ml). Similarly, the level of
IL-10 induced by CFP10 was also higher than that induced by
ESAT6, but the levels were not significantly different between
the patients with TB and the ECs (medians, 468 and 301 pg/ml,
respectively).
M. tuberculosis- and ESAT6-induced IFN- in TST and
TST healthy controls. Previous studies have described the
utility of ESAT6-stimulated IFN- responses for the detection
of latent TB (4) (12). Our healthy EC group comprised sub-
jects with both negative and positive TST reactions to purified
protein derivative, as determined by a positive induration
greater than or equal to 10 mm. We determined both the M.
tuberculosis- and the ESAT6-induced IFN- responses in both
TST and TST individuals. As shown in Fig. 2A, there was no
difference in the M. tuberculosis-induced IFN- response be-
tween TST and TST healthy controls. Compared with the
patients with TB, both TST and TST healthy controls se-
creted significantly greater levels of IFN- upon stimulation
with M. tuberculosis (P 0.037 and P 0.006, respectively). In
the same groups, the ESAT6-induced IFN- responses of the
TST controls were significantly reduced (P  0.008) com-
pared with those of the patients with TB (Fig. 2B). The
ESAT6-induced IFN- levels in the TST controls and the
patients with TB were comparable.
Mycobacterium-induced chemokine levels are raised in pa-
tients with TB. We subsequently investigated the Mycobacteri-
um-induced chemokine levels in the patients with TB and the
controls. The levels of secretion of CCL2, CCL3, and CXCL9
in the absence of stimulants were comparable between the
patient and the control groups (data not shown). Both M.
tuberculosis and BCG stimulated CCL2 secretion in all patients
with TB, while responses to either mycobacterium were
present in only a limited number (five or six) of ECs, and the
responses occurred in both TST and TST ECs. The level of
M. tuberculosis-induced CCL2 was significantly greater in the
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patients with TB than in the controls (P  0.006), Fig. 3A. The
level of BCG-induced CCL2 secretion also showed a trend to
be greater in the patients with TB, but the levels were not
significantly different between the patients and the controls
(P  0.074). The level of M. tuberculosis-induced CCL2 secre-
tion in the patients with TB was significantly greater than that
in response to BCG infection (P 
 0.01) (data not shown).
The levels of M. tuberculosis-induced CCL3 were compara-
ble between the patients and the controls (medians, 1,306 and
1,800 pg/ml, respectively), and the levels of BCG-induced
CCL3 were also comparable between the two groups (medians,
1,592 and 1,919 pg/ml, respectively).
The level of M. tuberculosis-induced CXCL9 was signifi-
cantly greater in the patients with TB (P  0.017) than in the
controls (Fig. 3B). The level of BCG-induced CXCL9 secre-
tion was negligible in both the ECs and the patients with TB
(medians 0 and 0, pg/ml, respectively) (data not shown).
ESAT6- and CFP10-induced chemokines in patients with
TB. The levels of ESAT6-induced CCL2 did not differ between
the patients with TB and the healthy controls (medians, 1,046
and 443 pg/ml, respectively). However, the level of CFP10-
induced CCL2 was significantly greater in the patients with TB
than in the healthy controls (P  0.01) (Fig. 4A).
The levels of ESAT6-induced CCL3 were comparable be-
tween the patients with TB and the ECs (medians, 1,567 and
1,590 pg/ml, respectively). CFP10 induced higher levels of
FIG. 1. Differential Mycobacterium- and mycobacterial antigen-induced IFN- responses in patients with TB. PBMCs (2  105) from the
patients with TB and the ECs were infected with M. tuberculosis or BCG at 2 105 CFU/well. Supernatants were harvested at 18 h poststimulation
for the measurement of IFN- and IL-10 levels. The data are shown as the means of individual experiments from the patients with TB (n  38)
and ECs (n  39). The box plots represent the data for each group after the level of cytokine secretion from unstimulated cells was subtracted.
The whiskers indicate the 25th and 75th quartiles, while a line indicating the median separates the two. *, significant differences between groups
(P 
 0.05). (A) IFN- induction by M. tuberculosis; (B) IFN- induction by BCG; (C) IL-10 induction by M. tuberculosis; (D) IL-10 induction
by BCG.
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CCL3 in the patients with TB, but the level was not signifi-
cantly greater than that in the ECs (medians, 2,076 and 2,200
pg/ml, respectively).
The levels of ESAT6-induced CXCL9 were similar between
the patients and the controls (medians, 0 and 0 pg/ml, respec-
tively). However, the level of CFP10-induced CXCL9 was sig-
nificantly greater (P  0.001) in the patients than in the con-
trols (Fig. 4B).
DISCUSSION
Our results indicate that the IFN- responses to a live my-
cobacterial infection caused by either virulent M. tuberculosis
or the avirulent BCG vaccine strain differ from those to my-
cobacterial antigens ESAT6 and CFP10.
The Mycobacterium-induced IFN- suppression observed in
the patients with pulmonary TB corresponds to the findings of
FIG. 2. Differential IFN- responses in TST and TST controls. Data for PBMCs from the TST and TST controls and the patients with
TB after stimulation with M. tuberculosis (A) or mycobacterial antigen ESAT6 (B) at 5 	g/ml and measurement of the levels of IFN- (IFNg)
secretion at 18 h postinfection are shown. Each data point is represented on the scatter graph, and median values are indicated by a horizontal
line.
FIG. 3. Increased levels of CCL2 (A) and CXCL9 (B) secretion in response to M. tuberculosis in patients with active TB. PBMCs from the
patients with TB and the ECs were infected with M. tuberculosis, as described in the legend to Fig. 1. The supernatants were harvested at 18 h
poststimulation for measurement of cytokine levels. The means of individual experiments with PBMCs from the patients with TB (n  38) and
ECs (n  39) are shown. The box plots represent data from each group after the levels of CCL2 and CXCL9 secretion from unstimulated cells
were subtracted. The whiskers indicate the 25th and 75th quartiles, while a line indicating the median separates the two. *, significant differences
between groups (P 
 0.05).
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previous studies, which indicate the lowering of T-cell-medi-
ated immunity in patients with TB (41). The increased levels of
M. tuberculosis- and BCG-induced IL-10 in the patients with
TB also corroborate previous data (41).
We found the ESAT6-induced IFN- responses to be in-
creased in the individuals with active TB. This also corresponds
to the findings of studies that have indicated that ESAT6-
induced IFN- may be an indicator of antigen-specific re-
sponses in infected individuals (35, 37). The levels of ESAT6-
induced IL-10 were not different between the controls and the
patients. Also, the levels of CFP10, which has previously been
shown to also elicit M. tuberculosis-specific IFN- responses in
infected individuals, were not found to be different between
the patients with TB and the healthy ECs.
Previous studies have correlated TST positivity with myco-
bacterial antigen-induced IFN- responses (4, 31) but have
shown that this correlation is decreased in BCG-vaccinated
donors (9). When we compared the IFN- responses of TST
and TST individuals, they were not significantly different, as
has previously been shown in areas with high rates of TB
transmission (3). As all subjects were BCG vaccinated accord-
ing to Pakistan immunization guidelines, TST positivity cannot
be attributed to BCG vaccination. As Pakistan has a very high
incidence of TB at 181/100,000 population (50), the possibility
of exposure to M. tuberculosis cannot be ruled out, nor can
exposure to environmental mycobacteria. Recent studies of
household contacts of patients with TB show that the time
postexposure at which the IFN- response to M. tuberculosis is
measured determines the cytokine profile obtained (23).
However, when the responses of both TST and TST
healthy controls were separately compared with those of the
patients with active TB, it was found that the TST individuals
made significantly larger amounts of IFN- in response to M.
tuberculosis than the patients with TB. These data indicate that
M. tuberculosis-specific immunity was primed in TST con-
trols, probably due to latent infection. When the responses to
ESAT6 were evaluated, it was found that the IFN- responses
of the TST controls were suppressed compared with those of
patients with active TB. These data indicate that protective
immunity to M. tuberculosis infection may be engendered by
antigens/epitopes other than the RD1 antigen ESAT6. Reports
by Demissie et al. have indicated that while ESAT6 may elicit
responses indicative of active TB infection, the responses to
other antigens, such as -crystallin, may be more useful for the
detection of latent infection (11). This has implications for
vaccine development, as ESAT6 is one of several candidate
antigens being employed in trials in which its protective efficacy
against M. tuberculosis is being tested (5, 32).
Recent literature has indicated an important role for CCL2
as an adjunct biomarker to be used with IFN- for assessment
of the response to M. tuberculosis infection (40). CCL2 levels
are increased in patients with pulmonary TB (20), and here we
have shown that the CCL2 level was increased in response to
both M. tuberculosis infection and BCG infection. In addition,
both ESAT6- and CFP10-induced CCL2 levels were increased
in the patients with TB. The magnitude of CCL2 elicited in
response to M. tuberculosis was significantly greater than that
elicited in response to BCG, indicating activation by specific
antigenic components. Of the recombinant antigens, the mag-
nitude of CCL2 secretion in response to CFP10 was found to
be greater than that in response to ESAT6. This further sug-
gests a role of CCL2 as a biomarker for the identification of M.
tuberculosis infection.
We found the level of M. tuberculosis-induced CXCL9 se-
cretion to be increased in the patients with TB, but BCG did
not induce CXCL9. Previous studies have shown increased
levels of CXCL9 in the PBMCs of patients with TB stimulated
with a recombinant fusion protein, ESAT6-CFP10 (1). Our
data indicate that the levels of ESAT6-induced CXCL9 were
not different between the patients and the controls, but the
FIG. 4. CFP10 is a more potent stimulator of CCL2 (A) and CXCL9 (B) in patients with TB. PBMCs from the patients with TB and the ECs
were stimulated with CFP10 at 5 	g/ml for 18 h, and the chemokine levels in the cell supernatants were measured. The means of individual
experiments with PBMCs from the patients with TB (n  38) and the ECs (n  39) are shown. The box plots represent data from each group after
the level of CXCL9 secretion from unstimulated cells was subtracted. The whiskers indicate the 25th and 75th quartiles, while a line indicating the
median separates the two. *, significant differences between groups (P 
 0.05).
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levels of CFP10-induced CXCL9 were increased in the patients
with TB. Therefore, it may be the CFP10 component of the
ESAT6-CFP10 recombinant protein that elicits CXCL9 acti-
vation.
These data are important, as an increasing amount of infor-
mation in the literature states the need to study biomarkers, in
addition to IFN-, for the testing of individuals for infection
with M. tuberculosis. However, ESAT6 and CFP10 remain the
antigens of choice. Recent studies compared the IFN- re-
sponse to H37Rv-encoded antigens, in addition to those of
RD1, including the antigen 85A complex, antigen 85A complex
peptides, and heparin-binding hemagglutinin adhesin (29, 30).
However, reports from regions where TB is endemic indicate
that the use of these antigens for the diagnosis of active TB
remains limited (3, 15). Therefore, it is important to use mul-
tiple antigens in screening assays in order to elicit a larger
number of antigenic responses. This may be particularly im-
portant in regions of endemicity with a larger number of la-
tently infected individuals. Such exposed individuals would re-
spond differently from uninfected community controls,
regardless of their TST positivity. Thus, it would not be possi-
ble to evaluate them by using the standard criteria expected of
the IFN- assays used in regions where TB is not endemic.
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